INS and type 2 diabetes mellitus: SCALE trial also reported GI AEs in patients with T2DM treated with injectable liraglutide versus placebo as an add-on to insulin basal therapy (71% vs. 49%), the most frequent being nausea, vomiting, constipation, diarrhea, or abdominal discomfort [19].